Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

NCT04221542 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT04221542
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04221542 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Recruiting
Start date
March 4, 2020
Completion date
March 21, 2032
Enrollment
479 (estimated)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer